Home/Filings/3/0000899243-21-038643
3//SEC Filing

Dainippon Sumitomo Pharma Co Ltd 3

Accession 0000899243-21-038643

CIK 0001635088other

Filed

Sep 30, 8:00 PM ET

Accepted

Oct 1, 5:00 PM ET

Size

6.2 KB

Accession

0000899243-21-038643

Insider Transaction Report

Form 3
Period: 2021-10-01
Holdings
  • Common Shares

    (indirect: See Footnote)
    86,367,360
Holdings
  • Common Shares

    (indirect: See Footnote)
    86,367,360
Footnotes (1)
  • [F1]Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon") directly owns 86,367,360 Common Shares. Sumitomo Dainippon is a 51.78% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo"). Sumitomo may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitomo Dainippon owns. Sumitomo disclaims beneficial ownership of such reported securities except to the extent of its pecuniary interest therein.

Issuer

Roivant Sciences Ltd.

CIK 0001635088

Entity typeother
IncorporatedJapan

Related Parties

1
  • filerCIK 0001446601

Filing Metadata

Form type
3
Filed
Sep 30, 8:00 PM ET
Accepted
Oct 1, 5:00 PM ET
Size
6.2 KB